3 results
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMORecruiting
1) to investigate if patients on chronic NOAC treatment are sufficiently anticoagulated without additional UFH during CAG/PCI, and 2) if this sufficient anticoagulation can be confirmed pre-procedure by a point-of-care test, and3) to investigate if…
Approved WMORecruiting
To determine wheter the use of the taurolidine 1.35%, citrate 4%, and heparin 100 IU/ml lock solution (TauroLock*-Hep100) reduces the incidence of first tunneled central line associated bloodstream inections (CLABSI) compared to the heparin 100 IU/…